Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The psychedelic experience can be challenging. There is a need for a structured framework for providing psychological support to individuals with mental health conditions receiving investigational psilocybin treatment. The primary benefit of such a framework is to support a safe and meaningful psilocybin experience. It also enables future research on the facets of psychological support and/or psychotherapy that most optimally complement psilocybin treatment. The authors describe the Compass Psychological Support Model (CPSM), currently used to support participants with treatment-resistant depression in Compass-sponsored clinical trials of investigational COMP360 psilocybin treatment. The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery.

Original publication

DOI

10.1176/appi.ajp.20230884

Type

Journal article

Journal

Am J Psychiatry

Publication Date

01/01/2025

Volume

182

Pages

126 - 132

Keywords

Clinical Drug Studies, Depressive Disorders, Drug/Psychotherapy Combination, Major Depressive Disorder, Psilocybin, Humans, Hallucinogens, Models, Psychological, Depressive Disorder, Treatment-Resistant, Psychotherapy